[
  {
    "ts": null,
    "headline": "Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell",
    "summary": "Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell",
    "url": "https://finnhub.io/api/news?id=3aaad96a7cb651577ac43ef514419da1d8f348d46856d2135fe96b074f05f3f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753708740,
      "headline": "Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell",
      "id": 136107341,
      "image": "",
      "related": "TECH",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3aaad96a7cb651577ac43ef514419da1d8f348d46856d2135fe96b074f05f3f9"
    }
  },
  {
    "ts": null,
    "headline": "Aristotle Large Cap Growth Q2 2025 Commentary",
    "summary": "For Q2 2025, Aristotle Atlanticâs Large Cap Growth Composite posted a total return of 18.63% gross of fees (18.45% net of fees).",
    "url": "https://finnhub.io/api/news?id=e553d355e78f6c843a168f5092c1f852bc28b4e5efd2d0d4ec5cba439f050757",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753702800,
      "headline": "Aristotle Large Cap Growth Q2 2025 Commentary",
      "id": 136107112,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195832722/image_2195832722.jpg?io=getty-c-w1536",
      "related": "TECH",
      "source": "SeekingAlpha",
      "summary": "For Q2 2025, Aristotle Atlanticâs Large Cap Growth Composite posted a total return of 18.63% gross of fees (18.45% net of fees).",
      "url": "https://finnhub.io/api/news?id=e553d355e78f6c843a168f5092c1f852bc28b4e5efd2d0d4ec5cba439f050757"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen",
    "summary": "Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target. The analyst told investors that Bio-Techne Corporation (NASDAQ:TECH) has potential for margin expansion and strong organic growth, and […]",
    "url": "https://finnhub.io/api/news?id=4c1c45c413ffae57c1569e7ff2495c5c5e48cb1eacbecd5b38e82ee34d880548",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682866,
      "headline": "Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen",
      "id": 136109022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target. The analyst told investors that Bio-Techne Corporation (NASDAQ:TECH) has potential for margin expansion and strong organic growth, and […]",
      "url": "https://finnhub.io/api/news?id=4c1c45c413ffae57c1569e7ff2495c5c5e48cb1eacbecd5b38e82ee34d880548"
    }
  }
]